The Effects of Postoperative Trimetazidine Treatment on Ischemia-Reperfusion Injury after Isolated Surgical Myocardial Revascularization
, , , et
30 sept. 2024
À propos de cet article
Catégorie d'article: Original Research
Publié en ligne: 30 sept. 2024
Pages: 89 - 94
Reçu: 25 juin 2024
Accepté: 15 sept. 2024
DOI: https://doi.org/10.2478/jce-2024-0019
Mots clés
© 2024 Stanev Kamen et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
hs-TNT levels in the two groups
| 12 h before surgery (%) | 19.9 ± 1.1 (18.3–22.1) | 20.5 ± 2.1 (18.3–31.1) | >0.05 |
| 12 h after surgery (%) | 187.2 ± 8.9 (165–206) | 186.8 ± 12.5 (166–221) | >0.05 |
| 6 months after surgery (%) | 19.4 ± 1.1 (17.9–22) | 19.6 ± 1.2 (18.1–22.3) | >0.05 |
MDA levels in the two groups
| 12- h before surgery (µmol/ml) | 236 ± 11 (223–243) | 232 ± 12 (219–244) | >0.05 |
| 12- h after surgery (µmol/ml) | 287 ± 18 (269–303) | 284 ± 20 (264–300) | >0.05 |
| 1- month after surgery (µmol/ml) | 227 ± 9 (211–233) | 270 ± 14 (260–282) | <0.05 |
| 6- months after surgery (µmol/ml) | 211 ± 7 (205–216) | 231 ± 13 (221–239) | <0.05 |
Postoperative data
| Cardiac ward stay (h) | 23.4 ± 2.9 (17–29) | 23.3 ± 2.6 (18–28) | >0.05 |
| In-hospital stay (days) | 6.8 ± 0.8 (5–8) | 7.1 ± 0.7 (5–8) | <0.05 |
| Total blood loss (ml) | 255.7 ± 60.6 (170–410) | 276 ± 66.2 (180–440) | >0.05 |
Intraoperative data
| CPB time (min), mean ± s.d. (range) | 43.7 ± 3.3 (38–51) | 43.5 ± 3.8 (38–55) | >0.05 |
| Aortic cross-clamp time (min), mean ± s.d. (range) | 27.4 ± 2.5 (22–31) | 28.2 ± 2.7 (21–34) | >0.05 |
| Number of bypass grafts performed, n | 135 | 135 | >0.05 |
| Venous bypass grafts, n | 90 | 90 | >0.05 |
| Off-pump procedures, n | nil | nil | – |
Demographic and preoperative characteristics
| Male sex, n (%) | 34 (75.6%) | 33 (73.3%) | >0.05 |
| Age (years) | 62.97±9.45 (55–72) | 64.18±6.54 (52–75) | >0.05 |
| BMI | 29.3 (23.1–32.4) | 29.6 (24.2–31.9) | >0.05 |
| Diabetes type 2, n (%) | 45 (100%) | 45 (100%) | >0.05 |
| Arterial hypertension, n (%) | 31 (68.8%) | 29 (64%9) | >0.05 |
| Hyperlipidemia, n (%) | 30 (66.6%) | 31 (68.8%) | >0.05 |
| Elective surgery, n (%) | 45 (100%) | 45 (100%) | >0.05 |
| Patients with implanted stents, n (%) | 11 (24%) | 14 (31%) | >0.05 |
| Total number of stents deployed, n | 16 | 19 | >0.05 |
| EuroSCORE II, mean ± s.d. | 1.6 ± 0.4 | 1.5 ± 0.7 | >0.05 |
LVEF in the two groups
| 12 h before surgery (%) | 44.1 ± 0.2 (41–51) | 45.2 ± 2.7 (41–51) | >0.05 |
| 1 h after surgery (%) | 43.8 ± 5.7 (38–48) | 44.6 ± 3.2 (39–51) | >0.05 |
| On discharge (%) | 47.5 ± 2.8 (43–53) | 47.8 ± 2.9 (43–55) | >0.05 |
| 6 months after surgery (%) | 54.4 ± 3.2 (48–62) | 53.9 ± 3.0 (49–57) | >0.05 |
CK-MB levels in the two groups
| 12 h before surgery (%) | 2.9 ± 0.2 (2.4–3.6) | 2.9 ± 0.2 (2.4–3.5) | >0.05 |
| 12 h after surgery (%) | 37.9 ± 5.7 (29–49) | 37 ± 5.9 (27–49) | >0.05 |
| 6 months after surgery (%) | 3.1 ± 0.4 (2.1–3.8) | 3.2 ± 0.3 (2.7–3.8) | >0.05 |